Alyeska Investment Group
CBIO

Alyeska Investment Group’s Crescent Biopharma CBIO Stock Holding History

Alyeska Investment Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-264,000
Closed -$4.85M – 716
2026
Q1 		$4.85M Hold
264,000
– – 0.01% 478
2025
Q4 		$3.11M Buy
+264,000
New +$3.36M 0.01% 494
2018
Q4 		– Sell
-4,501
Closed -$6.48M – 409
2018
Q3 		$6.48M Sell
4,501
-90
-2% -$136K 0.07% 220
2018
Q2 		$7.41M Sell
4,591
-279
-6% -$480K 0.07% 242
2018
Q1 		$7.9M Buy
4,870
+3,242
+199% +$6.74M 0.07% 250
2017
Q4 		$2.73M Sell
1,628
-1,962
-55% -$2.59M 0.02% 306
2017
Q3 		$5.02M Buy
3,590
+90
+3% +$106K 0.04% 293
2017
Q2 		$3.91M Buy
+3,500
New +$2.89M 0.03% 299
2015
Q4 		– Sell
-350
Closed -$196K – 412
2015
Q3 		$196K Buy
350
+32
+10% +$23.1K ﹤0.01% 449
2015
Q2 		$253K Buy
318
+5
+2% +$4.14K ﹤0.01% 473
2015
Q1 		$261K Buy
313
+23
+8% +$17.9K ﹤0.01% 483
2014
Q4 		$209K Sell
290
-11
-4% -$8.61K ﹤0.01% 467
2014
Q3 		$209K Sell
301
-4
-1% -$3.24K ﹤0.01% 371
2014
Q2 		$257K Sell
305
-447
-59% -$445K 0.01% 387
2014
Q1 		$1.23M Buy
+752
New +$910K 0.03% 285

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group's CBIO Position: Q2 2026 in Review

Alyeska Investment Group sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 264,000 shares — an estimated $4.85M sold.

Alyeska Investment Group first reported a position in CBIO in Q1 2014 and held it in 15 quarters. The position peaked at $7.9M in Q1 2018. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Alyeska Investment Group reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 264,000 Crescent Biopharma shares in Q2 2026, an estimated $4.85M.
  • Alyeska Investment Group first reported a position in Crescent Biopharma in Q1 2014 and held it in 15 quarters.
  • Alyeska Investment Group's Crescent Biopharma position peaked at $7.9M in Q1 2018.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.